

Corporate Presentation

July 2020

NASDAQ: NMRD



Forward-Looking Statements

- This presentation includes forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements, such as statements about Nemaura's short-term and long-term growth strategies, can sometimes be identified by use of terms such as "intend," "expect," "plan," "estimate," "future," "strive," and similar words. These statements involve many risks and uncertainties that may cause actual results to differ from what may be expressed or implied in these statements.
- These risks are discussed in Nemaura's filings with the Securities and Exchange Commission (the "Commission"), including the risks identified under the section captioned "Risk Factors" in Nemaura's Annual Report on Form 10-K filed with the Commission in June 2019 as the same may be updated from time to time.
- **Nemaura disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.**

Our Mission

- To disrupt the \$80B+ Diabetes & \$50B+ Pre-diabetes markets by making it much easier for people with diabetes and pre-diabetes to make lifestyle changes needed to manage, reverse or prevent diabetes.
- We achieve this by combining digital coaching and support services provided by **BEAT™ diabetes** with continuous glucose measurements (CGM) & daily glucose trend data provided by **SugarBEAT®**, the world's first CE Mark approved **Non-invasive CGM**.
- **Within 5 years Nemaura aims to lead in the wearables market and self-management** of medical conditions with our pipeline products of sensors and digital healthcare platforms using AI.
- **Employers, healthcare providers and insurers are already paying substantial fees** to support patients for the long term, using apps and coaching, so SugarBEAT® CGM combined with **BEAT™ diabetes** digital coaching are poised to disrupt this space.
- <https://sugarbeat.com/introducing-sugarbeat/>



Company Highlights


- World's first non-invasive CGM (continuous glucose monitor) SugarBEAT®, combined with digital coaching and support services provided by **BEAT™ diabetes** targeting \$179B+ Global opportunity:
 - Digital health sector comprising **\$69B+** Type 2 diabetes market¹
 - **\$50B+** Pre-diabetes market²
 - Wearable health-tech sector comprising **\$60B+** weight loss & wellness markets³
- US FDA PMA submitted and approval and launch anticipated by early 2021
- CE Mark Approved; UK & Ireland commercial launch planned for Q3 in UK and Germany, and Q4 in USA (in the wellbeing space for diabetes prevention, prior to PMA approval by FDA).
- Clean capital structure

1 PiperJaffray Company Note DXCM Sep 5 2018

2 Assuming 50% usage as compared to type II non insulin market

3 Juniper Research Digital Health Report Jan 14 2019



The Market



SugarBEAT® the Product



- CE Mark approved Class IIb device, adjunct to finger prick testing, for use by persons with diabetes
- Non invasive – sensor sits on top of the arm/skin
- Readings sent to mobile phone app every 5 minutes
- Intermittent wear time:
wear it when you choose
- Low cost
- Can be worn by anyone – for diabetes management, to aid diabetes prevention or for Wellbeing



How SugarBEAT® Works


- A small transmitter device and an adhesive patch with a sensor sits on top of the skin, typically on the upper arm.
- The system painlessly draws small amounts of glucose molecules out of the interstitial fluid just below the top layer of skin into a chamber within the patch. Does not require needles and sensor does not puncture the skin.
- The rechargeable transmitter measures glucose levels within the chamber, and transmits this data every five minutes via Bluetooth to a mobile phone app.
- Using a proprietary algorithm, the app then displays this data as glucose value on smart phone/device in graphical format as well as numeric values.

<https://sugarbeat.com>





BEAT™ diabetes Program



Commercialization & Sales – UK & Germany


- UK: Product planned for online sale direct to consumer. Drug tariff listing application in progress for reimbursement.
- Germany: Product planned for online sale direct to consumer. Application in progress for reimbursement.

Independent study outcomes provide compelling evidence for the use of CGM on non-consecutive days or a few consecutive days per month, to provide clinically significant outcomes in the management and/or reversal of Type 2 diabetes.

sugarBEAT® is ideally positioned to cater for this market over and above the incumbent invasive CGMs which have wear periods of up to 14 consecutive days with associated costs.



Consequently it may be possible to provide CGM to the majority of persons with Type 2 diabetes at an affordable cost point.

This has the potential to change the paradigm for the management of Type 2 diabetes on a global scale.



Commercialization & Sales - USA

- USA: PMA filed.
- Launch planned under the wellbeing category targeted at Type 2 diabetics as well as the pre-diabetes market (over 100 million potential users combined).
- Examples of incumbents in the space:
 - Omada, Livongo





Potentially game-changing moment for big data in the health industry

• The Value of Medical Data Realtime


- Mobile technology has been one of the largest contributors to big data for the past several years. Proliferation of mobile phones, the implementation of app-enabled smart phones, and now the growth of the wearable device market are all creating massive new data flows that can be put to use for health and other purposes.
- Wearable medical devices are not new, but they have long been expensive and not always viable for every patient or subject of a medical study to wear. That's why the growth of the wearable personal electronic device market – and the lower prices that come with a higher volume of devices being sold – is such a potentially game-changing moment for big data in the health industry

• Extracting personal data from wearable Medical devices:

- Predictive analytics is based on logic that is drawn from the wearable Medical devices uses an algorithm to seek patterns and structure in data and cluster them into groups or insights.
- Improving efficiencies per patient's management of health care
- Accuracy of diagnosis and treatment in personal medicine
- Increased insights to enhance lifestyle, diabetes, drug management and cohort treatment

• Development of Artificial Intelligence and intermittent testing using SugarBEAT® has the potential to disrupt diabetes management from the following perspectives:

- Empowering users with interpretations of SugarBEAT® data. Empowering Industry such as Big Pharma to enhance drug treatment regimens and develop personalized therapy.
- Seeking to capitalize on this groundbreaking approach to making large datasets more accessible, the U.S. National Institutes of Health — the preeminent U.S. government medical research organization, which oversees an annual \$31 billion budget — is now working with IBM to connect a very wide variety of clinical and research datasets to the IBM Watson system.



SugarBEAT®

NASDAQ: NMRD

Nemaura vs Livongo®

*The technical difference!
Starts with a supporting approved medical device.*

• The Trends In Mobile Healthcare

- What we are seeing is a shift towards digital medical care. The records are more often kept electronically, there are more opportunities for remote patient monitoring, and more tools for individual health monitoring are emerging. Digital health deals are booming: the value of investments reached \$7.5 billion in 2019².





• Nemaura is the latest breakthrough in mobile/wearable healthcare technology regarding functionality, technology, interconnectivity and all supported with real medical diagnostics from their CE approved medical device.

• Livongo® Limitations: (NASDAQ: LVGO)

- **Livongo® for Diabetes:** includes a cellular- connected interactive glucometer, unlimited blood glucose test strips, real-time coaching, and 24-hour monitoring
- **Livongo for Pre-Diabetes and Weight Management:** offers a cellular-connected weight scale, health educational content, personalized coaching service, and group classes

• Nemaura Advantages:

- **SugarBEAT® CGM provides very powerful data** that will allow long term therapy and lifestyle adjustments that finger prick testing cannot achieve
- **Clinically proven, evidence based health education on diabetes that has been demonstrated to lead to behavioral changes in diabetics.** On-demand coaching service for personal fitness, motivation, and dietary advice, (through in-licensing and collaboration)



1. Livongo® is a registered trademark of Livongo Health, Inc.

2. <https://www.digitalhealth.net/2020/01/ces-2020-digital-health-investment-2019/>

Opportunities for application of big data in the health industry

The Value of Medical Data Realtime


- Mobile technology has been one of the largest contributors to big data for the past several years. Proliferation of mobile phones, the implementation of app-enabled smart phones, and now the growth of the wearable device market are all creating massive new data flows that can be put to use for health and other purposes.
- Wearable medical devices are not new, but they have long been expensive and not always viable for every patient or subject of a medical study to wear. That's why the growth of the wearable personal electronic device market – and the lower prices that come with a higher volume of devices being sold – is such a potentially game-changing moment for big data in the health industry

Extracting personal data from wearable Medical devices:

- Predictive analytics is based on logic that is drawn from the wearable Medical devices uses an algorithm to seek patterns and structure in data and cluster them into groups or insights.
- Improving efficiencies per patient's management of health care
- Accuracy of diagnosis and treatment in personal medicine
- Increased insights to enhance lifestyle, diabetes, drug management and cohort treatment

Initial development of Artificial Intelligence and intermittent testing using SugarBEAT® has the potential to disrupt diabetes management from the following perspectives:

- Empowering users with interpretations of SugarBEAT® data. Empowering Industry such as Big Pharma to enhance drug treatment regimens and develop personalized therapy.
- Seeking to capitalize on this approach to making large datasets more accessible, the U.S. National Institutes of Health — the preeminent U.S. government medical research organization, which oversees an annual \$41.7 billion budget¹ — is now working with IBM to connect a very wide variety of clinical and research datasets to the IBM Watson system.



1. <https://www.nih.gov/about-nih/what-we-do/budget>

Continuous glucose monitoring (CGM): TAM

Country	Population	Prevalence	People with Diabetes	Type 1 (5%)	Type 2 Insulin (15%)	Type 2 Non-Insulin (80%)	Type 1 (365 days)	Type 2 Insulin (365 days)	Type 2 Non-Insulin (56 days)
United Kingdom	66,622,517	5.0%	3,356,396	167,820	503,459	2,685,117	\$214,389,821	\$643,169,463	\$526,282,958
Ireland	4,809,026	3.8%	182,787	9,139	27,418	146,229	\$8,339,650	\$25,018,949	\$20,472,126
Germany	82,315,845	10.7%	8,807,795	440,390	1,321,169	7,046,236	\$562,597,932	\$1,687,793,796	\$1,381,062,321
U.S.	327,055,816	10.3%	33,662,880	1,628,312	4,770,007	27,264,561	\$2,080,169,053	\$6,093,683,980	\$5,343,853,864

SugarBEAT® \$179B+ Global Market opportunity consists of three target markets:¹

- \$69B+ TAM Type 2 diabetes (90% of all people with diabetes)
- \$50B+ TAM Pre-diabetes — approximately 3x population
- \$60B+ TAM Wearable Health-Tech market: low carb / weight loss / fitness

U.S. CGM Market Overview ²

- U.S. has the largest number of CGM users globally (630k in 2018) Only 2.6% of 25M US diagnosed diabetics used CGM in 2018
- U.S. annual CGM usage increased by 117% in 2018 30% of U.S. Type 1 people with diabetes use CGM
- 3% of U.S. Type 2 insulin users use CGM

CGM usage amongst non-insulin diabetics negligible

- U.S. has 84M People with Pre-diabetes


The number of people that could benefit from SugarBEAT® is significant but even in a scenario where this was only rolled out across staff considered to be high value assets to the 100 biggest companies in the UK, we forecast this having the potential of achieving over 200,000 subscribers in the UK alone.

NHS (UK) Diabetes Prevention Program (DPP) Digital Stream

- DPP to support 200,000 people per year to transform their lifestyles
- Five digital behavior change providers
- Based on continuous engagement with patients to make new habits and behaviors
- Help patients to improve their conditions by personalized health lifestyle plans and coaching

NHS (UK) Type 2 behavior change at scale

- Partnership with NHS England offering free digital support for people diagnosed with Type 2 diabetes
- Online platform will deliver this behavior change service nationally
- Evidence based education with innovative technology to provide personalization at scale




Understanding the opportunity



Current Product Pipeline



Product	Key Features	Market
SugarBEAT® Gen II	<ul style="list-style-type: none"> • Include pediatric cover • Improved accuracy (MARD) • Longer patch wear time • Include Gestational use 	<ul style="list-style-type: none"> • Type II Diabetics • Pre-Diabetics • Wearable Health-Tech • Pregnancy
Continuous Lactate Monitoring	<ul style="list-style-type: none"> • World's only non-invasive skin patch for continuous lactate monitoring • Determines appropriate training intensity levels and monitors progression 	<ul style="list-style-type: none"> • Athletes • Fitness • Wearable Health-Tech market expected to be worth \$60B+ by 2023¹



Future Product Pipeline

Product	Uses	Diagnostics
Alcohol Monitoring	Support personal health goals, and provide warnings prior to driving, and provide physicians with individual drinking habits	Prevention of progression to alcohol related diseases.
Prostaglandin Monitoring	Screening for inflammatory irritants in formulations during drug and cosmetic development	Inflammation
Lactate Monitoring	Lactate monitoring in intensive care	Anaerobic Metabolism
Drug Monitoring	Monitoring the impact of drug treatment for treatment-regimen calibration and pharmacokinetics	Treatment Regimen Optimization
Continuous Temperature monitoring	Temperature monitoring for monitoring viral infections, and lower limb blood circulation	Viral infections and tissue necrosis

The Management Team



Dr. Faz Chowdhury
Chief Executive Officer

Dr. Chowdhury has served as CEO and chair of the board of Nemauro Medical since formation in December 2013. He is sole inventor on more than 100 granted and pending patents across over 20 technology platforms within the medical device and pharmaceutical sectors. He has 20 years experience and track record taking products from concept to approval, and has been pivotal in the company's technical and strategic development.

He has authored Textbook Chapters on Nanobiosciences for Wiley and Elsevier, and serves on the Board of Medilink East Midlands, UK. Dr. Chowdhury holds a Masters in Microsystems and Nanotechnology from Cranfield University, UK, and Doctorate from the University of Oxford on nano-medicine and drug delivery.



Dr. Fred Schaebdsau
Vice President,
Strategy & Strategic Alliances

Dr. Schaebdsau has over 15 years of executive level experience in the CGM, Blood Glucose Monitoring (BGM) and insulin delivery industries, which started in 2004 during his tenure with Abboq Diabetes Care, where he was a member of the M&A and post-merger integration teams responsible for the acquisition of TheraSense and its FreeStyle Navigator CGM.

From September 2016 until January 2019, he was the General Manager of Dexcom Germany, which during his leadership became the fastest growing organization in Dexcom's history achieving triple digit revenue and new patient growth every year.



Chris Avery
Vice President,
Global Business Operations

Mr. Avery has 35 years' experience in diabetes, gaining vast experience in glucose monitoring and insulin delivery markets. He co-founded a UK diabetes distributorship in 2000 and served as UK Managing Director and European Director later acquired by Nipro.

To date he has successfully launched over 20 glucose systems either direct or with distributors and negotiated partnerships and distribution deals with pharmaceutical & medtech companies across Europe and other international markets. In 2016 he joined Nemauro Medical's European JV partner, Dallas Burston Ethitronix as SVP Global Business Development, and worked closely with Dr. Chowdhury until joining Nemauro Medical in June 2019.



SugarBEAT® Clinical Data

- Completed clinical studies for FDA PMA submission
 - The clinical studies used were split between Type 1 and Type 2 diabetics
 - Consisted of 75 patients over 225 patient days
 - Generated over 12,000 paired data points, with blood samples taken via catheter every 15 minutes over a 12-hour period for three non-consecutive days for each patient
- Study design was based on two previous pre-sub meetings Nemaura held with the FDA
- The clinical study results indicated a MARD (Mean Absolute Relative Deviation) of 12.50% (with a lower figure denoting greater accuracy), using a single point finger stick calibration, and 10.75% with 2 finger prick calibrations
 - No device-related adverse events were noted

Manufacturing

- **Transmitter device and charging station**
 - All manufactured in the UK and can be readily scaled to by adding multiple lines to what is a linear operation.
- **Disposable skin adhesive and ancillary disposable parts**
 - All manufactured in the UK and can be readily scaled to millions of units per month.
- **Disposable daily sensor**
 - All manufactured in the UK and can be readily scaled to millions of units per month, by adding multiple lines to what is a linear operation.
- **Manufacturing scale**
 - **Current scale** will allow us to launch in the UK, Ireland and Germany.
 - **Future manufacturing** will be outsourced to various low cost regions for the non-specialized parts, but sensor production to remain in UK.



Intellectual Property

Building an extensive intellectual property portfolio to position the Company to become a leader in the non-invasive CGM space

The Company has over thirty patents (~70% approved and ~30% pending) spanning the following patent families:

1. Sensor related
2. Algorithm and methods of using the CGM data
3. Devices & methods to enhance glucose sensing
4. Methods to enhance glucose sensing
5. Devices and methods to extract glucose

The Company anticipates filing multiple additional patents over the course of the next 18 months based on ongoing findings and improvements.



Summary

- **Nemauro Medical aims to dominate the global diabetes markets** for putting Type 2 diabetes into remission, using the SugarBEAT® device and digital healthcare platform.
 - Within 5 years the company aims to lead in the wearables market and self-management of medical conditions with its pipeline products of sensors and digital healthcare platform using AI.
 - The company has the potential to disrupt the multi-Billion dollar glucose trending and diabetes management space targeting \$179B+ Global opportunity:
 - Planned Launch of SugarBEAT® in key global territories by 2020 and aiming for 1 million users by 2021, and 3 million users by 2023
- **Digital health sector comprising \$69B+ Type 2 diabetic market & \$50B+ pre-diabetic market**
 - Aiming to build on the Livongo model, but using the company's proprietary unique device platform, hence a more substantial investment proposition
 - Wearable health-tech sector comprising \$60B+ weight loss & wellness markets
 - US approval and launch anticipated by end of 2020
 - CE Mark Approved; UK & Ireland commercial launch expected in Q1 2020, followed by Germany
 - Lowest priced, high recurring margin model, with lowest COGS per CGM patch in the industry
- **Growing IP portfolio with over 30 issued & pending patents**
 - Launching continuous lactate monitoring (CLM) near term, targeting \$60B+ wearable tech market
 - Pipeline of four other products including non-invasive continuous alcohol monitoring (CAM)
- **Proven management team with successful track records**
- **Clean capital structure**

